Andriol is a hormonal drug that contains testosterone. Testosterone is an endogenous hormone necessary for the normal development of male genital organs and secondary sexual characteristics, to maintain normal function of the testicles, prostate gland and seminal vesicles, maintaining libido and potency. The use of the drug for the treatment of hypogonadism in men leads to a clinically significant increase in plasma concentrations of testosterone, dihydrotestosterone and androstenedione and a decrease in globulin binding sex hormones (SHGG). In men with primary (hypergonadotropic) hypogonadism, the use of the drug leads to a normalization of gonadotropin concentration.
Testosterone undecanoate + excipients.
After ingestion, a significant portion of Andriol along with the lipophilic solvent is absorbed into the small intestine and enters the lymphatic system, thus avoiding the primary passage through the liver. With the absorption of testosterone, undecanoate is partially reduced to form the dihydrotestosterone undecanoate. From the lymphatic system, he enters the plasma. In the plasma and tissues, as a result of the hydrolysis of testosterone undecanoate and ditrotestosterone undecanoate, the natural male sex hormones testosterone and dihydrotestosterone are released. A single dose of 80-160 mg of Andriol leads to a clinically significant increase in the total plasma concentration of testosterone, Cmax is approximately 40 nmol / L and is achieved 4-5 hours after administration. The increased concentration of testosterone is retained, but at least within 8 hours. It is excreted primarily with urine in the form of conjugates (etiocholanolone and androsterone).
At simultaneous application with inductors of enzymes of microsomal oxidation (barbiturates, rifampicin), a decrease in the effectiveness of the drug is possible.